Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the Board of Directors has appointed Evelyn Graham as the Company's Chief Executive Officer and as a member of the Company's Board of Directors. Ms. Graham had been serving as the Company's acting Chief Executive Officer since September 1, 2008.

"Ev has done an impressive job as acting CEO in managing the transition of our company and building a platform for the future," said Peter Davis, Chairman of the TorreyPines Board of Directors. "We are delighted that she has agreed to become CEO and a member of the Board at a time when TorreyPines is completing important clinical trials that hold promise for the company's future. With her considerable drug development experience as well as global senior management roles, she has the right mix of skills and experience to successfully lead the Company in meeting its strategic objectives."

"I am excited by this opportunity and look forward to continuing to work with TorreyPines' talented management team and dedicated employees," said Ms. Graham.

Ms. Graham joined TorreyPines in 2004 as Vice President, Development. She was then promoted to Vice President, Corporate Development in 2005, Chief Operating Officer in 2006 and acting Chief Executive Officer in September 2008. Prior to joining TorreyPines Ms. Graham was Executive Director, Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000, she was Senior Vice President of Business Development at Ingenix Pharmaceutical Services, a division of UHG, and served as Vice President of Clinical Operations at Worldwide Clinical Trials, prior to its acquisition by UHG. Previously, Ms. Graham held positions in oper
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014 The Alliance ... a survey of European physicians at the "1 ... and Biological Therapies" at the Spanish Ministry of ... by EuropaBio and the Spanish Bioindustry Association (ASEBIO), ... physicians from Spanish oncology and rheumatology societies, representatives ...
(Date:11/26/2014)... Whitehouse Laboratories is pleased to announce ... (New Jersey) Chamber of Commerce as a member. ... in the North Jersey area, offers Whitehouse Laboratories ... clients in the pharmaceutical and biotechnology areas that ... enables Whitehouse Laboratories a higher level of visibility ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 The Pittcon ... its official conference and exposition mobile app, ... free download in the App Store for iOS and ... valuable resource tool before, during and after the event. ... details on exhibiting companies, technical sessions, Conferee Networking sessions ...
(Date:11/26/2014)... PLAINSBORO, N.J. and WILMINGTON, DE (PRWEB) November 26, 2014 ... the 2nd Annual MPN Heroes recognition reception on December ... Society of Hematology’s annual meeting. The MPN Heroes event ... significant contributions in the field of myeloproliferative neoplasms (MPNs). ... TV show "Nashville," will discuss his family's cancer journey ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... September 2 According to a new,market research ... MarketsandMarkets ( http://www.marketsandmarkets.com ), the global,biosimilars market is ... recording,a CAGR of 89.1% from 2009 to 2014. ... to reduce the costs of blockbuster,biopharmaceuticals has created ...
... , WALTHAM, Mass., Sept. 2 Repligen Corporation ... and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at ... 9th, 2009 at 2:25 p.m. EDT at the New York Palace ... webcast of the presentation will be available via Repligen,s website at ...
... of the problem: In a swarm of small fish it ... found in the microcosm of atoms and molecules, whose behavior ... control over single electrons in a bunch, ultrashort light pulses ... Max Planck Institute of Quantum Optics (MPQ) in Garching and ...
Cached Biology Technology:MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014 2MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014 3Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT 2Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT 3Laser pulses control single electrons in complex molecules 2Laser pulses control single electrons in complex molecules 3
(Date:11/4/2014)... at the right time might actually help boost a ... help in understanding animal populations, pest control and managing ... the journal Trends in Ecology and Evolution , ... the kind of positive population effect an overall species ... on the size and developmental stage of the creatures ...
(Date:11/4/2014)... about the way our bodies are assembled during early ... they are supposed to become a nerve or a ... correct place and alignment? Researchers at the University of ... a new study, UM researchers describe the signaling systems ... at the head-trunk region. Their discovery may have important ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... NEW YORK , Aug. 15, 2013   ... authentication solutions, announced today the appointment of Michael ...  Fiorito,s appointment reinforces the adoption and expansion of ... enterprise market. In this role, Fiorito ...
... German researchers have identified four biomarkers that correctly determine ... accurate prediction of patient outcomes. Their results are published ... Molecular Diagnostics . Current prognosticators of bladder cancer, ... foci, have limited usefulness for clinicians since they do ...
... who often recall their dreams respond more strongly to their ... mysteries of human cognition. It is still not fully known ... them. A major difficulty for studying dreams is that they ... Ruby and colleagues from the Lyon Neuroscience Research Center chose ...
Cached Biology News:EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts 2MicroRNAs have diagnostic and prognostic potential in urinary bladder cancer 2Frontiers news briefs: Aug. 13 2Frontiers news briefs: Aug. 13 3